Bajaj Healthcare Ltd’s shares soared by 5% to reach a 52-week high of ₹456, following approval from the Therapeutic Goods Administration (TGA) of Australia for its Active Pharmaceutical Ingredient (API) manufacturing site in Savli, Vadodara, Gujarat.
The site, already approved by the US FDA and EU authorities, strengthens the company’s global credentials in regulated markets. This TGA recognition enables Bajaj Healthcare to directly supply APIs to Australia and New Zealand and cater to manufacturers exporting finished products to these territories.
The milestone highlights Bajaj Healthcare’s growing footprint in global pharmaceutical markets, bolstering its reputation for compliance and quality.
Bajaj Healthcare shares opened today at ₹437.95, with a high of ₹456.00 and a low of ₹425.60. The stock has a 52-week high of ₹456.00 and a 52-week low of ₹263.30.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
